Drug facts

Molecule

Dexamethasone

Generics already compete: 14 makers on the market. 47 A-rated products from 13 makers substitute at the counter.

Decadron was first approved by the FDA before 1982 under NDA 011664; the application holder is Merck and Co Inc. The Orange Book lists NDA 011664 as discontinued.

Dexamethasone Sodium Phosphate Injection is on the current FDA drug shortage list, first posted 02/08/2019.

Holder Merck and Co IncApplication NDA 011664Approved before 1982

01Patents and exclusivity

When competition can legally begin. A generic can launch once both exclusivity and the last listed patent expire, unless a court or settlement says otherwise.

Latest patent
No Decadron patent listed in the Orange Book
Orange Book
Later patents, other products
Dextenza 04/26/2041; Dexycu Kit 06/23/2039; Hemady 12/18/2037
Orange Book

02Competition

Generics
14 generic makers
Orange Book
First generic approved
before 1982
Orange Book
Every listingEach listing and maker behind the generics count.
Price erosionHow NADAC moves as generics enter.
PrescribersWho prescribes it, from Medicare data.
Available in the full Dexamethasone profile.See what is included

03Supply and price

FDA drug shortage
ActiveDexamethasone Sodium Phosphate Injection is on the current shortage listsince 02/08/2019, available
FDA shortages
NADAC
$0.18 per unitDEXAMETHASONE 1.5 MG TABLET, mid-priced of 7 strengths, as of 10/28/2026
CMS NADAC
Latest recall
12/22/2022Class II, Dexamethasone 16mg/Ml, Pharmacy Innovations
FDA enforcement

04Product

Application holder
Merck and Co Inc
Orange Book
Application
NDA 011664
Orange Book
First approved
before 1982
Orange Book
Dosage forms
concentrate; elixir; implant; insert; solution; suspension/drops
Routes
intravitreal, ophthalmic, oral
Other brand names
DextenzaHemadyMaxidexOzurdex
Status
NDA 011664 discontinued
Orange Book

Sources: FDA Orange Book, FDA Purple Book, FDA drug shortages, FDA enforcement reports and CMS NADAC, read through QOPE. Not medical or legal advice.